OCU400 demonstrated meaningful improvement of 2-line gain (10 letters on ETDRS chart) in low-luminance visual acuity (LLVA) in treated eyes when compared to untreated fellow eyes. Ocugen, Inc.

The Phase 3 OCU400 liMeliGhT trial is progressing towards a BLA submission in the first half of 2026. OCU400 demonstrated meaningful improvement of 2-line gain (10 letters on ETDRS chart) in ...

The UK’s biggest Afrobeats songs of the week based on sales and streams across a seven day period, compiled by the Official Charts Company.

EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...

The patients’ LogMAR (Logarithm of the Minimal Angle of Resolution) scores, which are derived from the number of letters patients read on the ETDRS chart, were used for statistical purposes.

with a best corrected visual acuity letter score of at least 54 as measured by the ETDRS chart. Changes in BCVA, low-luminance visual acuity (LLVA) and OCTA metrics were recorded over 12 months.

Please note, the data displayed for this chart reflects the title's midweek position only, peak positions on this chart also relate to midweek chart positions. Official Singles Chart Update data ...

Notably, treated eyes achieved a statistically significant two-line gain (10 letters) in low-luminance visual acuity (LLVA) on the ETDRS chart, regardless of genetic mutation, with a p-value of 0.01.

Informed consent was obtained from each subject. Presenting visual acuity (with spectacles if worn) was measured in each eye separately at 4 metres using the reduced logMAR tumbling E chart, 5 which ...